SCHEMBL4879918

SCHEMBL4879918

c1coc(-c2ccc(C3CC4CCC(C3)N4)nn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.43
RAB9A P51151 9/20 0.43
KDM4E B2RXH2 7/20 0.43
NPC1 O15118 7/20 0.43
BLM P54132 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 5/20 0.40
SMN1; SMN2 Q16637 8/20 0.38
POLB P06746 6/20 0.38
TP53 P04637 1/20 0.38
MDM2 Q00987 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
APAF1 O14727 1/20 0.36
NSD2 O96028 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
SAE1 Q9UBE0 1/20 0.36
UBA2 Q9UBT2 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4873529 0.74 PBRM1 (0.35) ALDH1A1MEN1KMT2AMAPTTP53
SCHEMBL13528568 0.74 ALDH1A1 (0.68) ALDH1A1RAB9AKDM4ENPC1BLM
SCHEMBL4876561 0.71 RAB9A (0.45) ALDH1A1RAB9AKDM4ENPC1MEN1
SCHEMBL24610476 0.70 MAP3K12 (0.40) ALDH1A1MEN1KMT2ATDP1
SCHEMBL21081197 0.70 MAP3K12 (0.40) ALDH1A1MEN1KMT2ATDP1
Hydrochloric Acid SCHEMBL21045945 0.69 MAP3K12 (0.39) ALDH1A1MEN1KMT2ATDP1
SCHEMBL4876306 0.69 CHRM2 (0.34) NPC1
SCHEMBL11153519 0.64 ALDH1A1 (0.56) ALDH1A1RAB9AKDM4ENPC1BLM
SCHEMBL15173265 0.64 ALDH1A1 (0.56) ALDH1A1RAB9AKDM4ENPC1BLM
SCHEMBL12741374 0.62 OPRM1 (0.44) ALDH1A1RAB9AKDM4ENPC1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153806-A1 Novel Diazabicyclic Aryl Derivatives And Their Medical Use NEUROSEARCH A/S (DK) 2008-06-26 US claimed
EP-1805183-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-07-11 EP claimed
WO-2006045716-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-05-04 WO claimed
US-20080153806-A1 Novel Diazabicyclic Aryl Derivatives And Their Medical Use NEUROSEARCH A/S (DK) 2008-06-26 US disclosed
EP-1805183-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-07-11 EP disclosed
WO-2006045716-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153806-A1 Novel Diazabicyclic Aryl Derivatives And Their Medical Use CHRNA6, CHRNA10, CHRNA2 ALDH1A1 824/4885RAB9A 2853/4885KDM4E 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.